FRAGMENT 176-191 5mg

- Free Priority Shipping
- Orders over $75
FRAGMENT 176-191 5mg:
| Unit Size | 5 mg/vial |
| Unit Quantity | 1 vial |
| Purity (Mass Spectrometry and UV) | 99.56% |
| Sequence | H-Phe-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-OH |
| Molecular Formula | C78H123N23O22S2 |
| Appearance | Lyophilized White Powder |
| Source | Chemical Synthesis |
| Storage | Lyophilized Fragment 176-191 is stable at room temperature for up to 90 days. For extended storage, keep in a freezer at -20°C. |
| Terms | The products we offer are intended for laboratory research use only. Please familiarize yourself with our terms of service prior to ordering. |
FRAGMENT 176-191 5mg
View Research Overview & References
Fragment 176-191 is a synthetic 16-amino-acid peptide corresponding to residues 176 through 191 at the C-terminus of growth hormone (hGH), with a molecular weight of approximately 1799 g/mol.1
Sequence Relative to Related Analogs
Fragment 176-191 begins with phenylalanine at its N-terminus, matching the native hGH sequence. It is distinct from AOD-9604, a related analog that carries tyrosine in that position, and the two compounds differ in molecular formula and mass.
Peptide Structure and the Cys7–Cys14 Disulfide Bridge
A defining structural feature of Fragment 176-191 is the intramolecular disulfide bond formed between its two cysteine residues, which constrains the peptide into a looped conformation not present in a fully linear hGH-derived fragment.
This structural detail is a frequent point of reference when comparing synthesis routes across suppliers, since correct disulfide formation, rather than a free-thiol reduced state, determines which form of the peptide is present in a given lot.
Analytical Purity and Disulfide Bond Verification
Beyond standard sequence confirmation by mass spectrometry, laboratory-grade Fragment 176-191 requires verification that the Cys7–Cys14 disulfide bond has formed correctly rather than the peptide remaining in its reduced, linear state. Both forms share the same amino acid sequence but differ slightly in mass and in chromatographic behavior.
HPLC combined with mass spectrometry is used to distinguish the oxidized (cyclic) form from residual linear peptide, and researchers designing dose-response experiments are encouraged to review lot-specific analytical data confirming the oxidized state alongside the standard purity percentage.
Storage and Handling in the Laboratory Setting
Peptides containing disulfide bonds are susceptible to reduction under certain storage conditions, particularly in the presence of reducing agents or extended exposure to light and elevated temperature.
Laboratories typically store lyophilized Fragment 176-191 under sub-zero freezer conditions, which helps preserve the oxidized disulfide state.
Comparative Research Context Among hGH-Derived Fragments
Fragment 176-191 is one of several hGH-derived research peptides studied for isolating specific regions of the full-length hormone, distinct from growth hormone secretagogues such as GHRP-class peptides that act upstream at the pituitary.
Researchers comparing these peptide classes often cite Fragment 176-191's restriction to the hormone's C-terminal domain as a way to study this region separately from the IGF-1-associated domains of the full-length hormone.
Telling Fragment 176-191 and AOD-9604 Apart
These two peptides are frequently confused, and the chemical difference between them is small. Both are 16 residues long and share fifteen of those residues identically. They diverge only at the first position, where Fragment 176-191 carries phenylalanine and AOD-9604 carries tyrosine.
Tyrosine is phenylalanine with a single hydroxyl group added to its aromatic ring. The entire structural difference between the two compounds is therefore one oxygen atom, which translates to roughly 16 Da of mass.
On a mass spectrum that is a modest shift, well within the resolving power of standard instrumentation but easy to overlook if an analyst is not specifically checking for it. Confirming the reported mass against the expected value for the stated formula, rather than accepting a product name at face value, is the reliable way to establish which of the two a given lot contains.
UV Detection and the Absence of Tyrosine
That same single-atom difference has a practical consequence for detection. Peptides are commonly monitored at 280 nm, a wavelength where tryptophan and tyrosine absorb strongly. Fragment 176-191 contains neither residue.
Its two phenylalanines absorb only weakly and at shorter wavelengths, so chromatographic analysis of this peptide relies on detection at 214 to 220 nm, where the peptide bonds themselves absorb. AOD-9604, by contrast, does carry a tyrosine and produces a clear 280 nm signal, which is one more analytical handle for distinguishing the two.
Arginine Positions and Peptide Mapping
The sequence contains two arginine residues, at positions 3 and 8, and no lysine at all. This matters for peptide mapping, a confirmation technique in which a peptide is enzymatically digested and the resulting pieces are identified by mass.
Trypsin, the enzyme most commonly used for this purpose, cleaves after arginine and lysine residues. With only two cleavage sites, Fragment 176-191 yields a short and highly predictable set of fragments, which makes the resulting map straightforward to interpret.
Choosing Between the Available Unit Sizes
At 5 mg per vial, this unit carries two and a half times the peptide mass of the 2 mg presentation. For a study spanning many conditions or replicates, drawing from a single larger vial keeps the entire dataset tied to one lot and one certificate of analysis, removing batch variation as a factor when results are compared across runs.
Product Information
Fragment 176-191 is supplied as a lyophilized white powder at 5 mg per vial.
Important Notice
This product is intended for laboratory research use (in vitro) only. It is not approved for human use under any circumstances, and has not been evaluated for safety or efficacy in humans.
References
1. Harvey S, Martinez-Moreno CG. Growth Hormone: Therapeutic Possibilities—An Overview. Int J Mol Sci. 2018;19(7):2015.








